Blog Posts - Harvoni



DEMOCRATS ARE DOING NOTHING TO STOP TRUMP FROM ASCENDING TO POTUS

DEMOCRATS ARE DOING NOTHING TO STOP TRUMP FROM ASCENDING TO THE POTUS INSTEAD THEY ARE CONCENTRATING ON PACKING THE SENATE WITH NEW DEMOCRATIC MEMBERS NJ SENATOR MENENDEZ IS BUSY ASKING PEOPLE LIKE ME FOR MONEY BUT NOTHING HAS BEEN SAID OR WRITTEN FR...
by The Politics of Everything on Dec 7, 2016

Shorter HCV Tx Works in Advanced Disease

Provided by MedPage Today Twelve weeks of treatment yielded high efficacy rates in hepatitis C (HCV) patients with advanced liver disease or recurrent HCV after transplant. by Michael Smith North American Correspondent, MedPage Today VIENNA --...
by Hepatitis C Research and News on Apr 23, 2015

Gilead’s Harvoni and Sovaldi Demonstrate Efficacy and Safety among Chronic Hepatitis C Patients with Advanced Liver Disease

-- High Cure Rates in More Than 600 Genotype 1 and 4 Patients With Limited or No Approved Treatment Options -- VIENNA, Austria--(BUSINESS WIRE)--Apr. 23, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from several Phase 2 clinic...
by Hepatitis C Research and News on Apr 23, 2015

B.C covers two curative hepatitis C drugs

Monday, March 23, 2015 3:00 PM VICTORIA - British Columbia is providing public drug plan coverage of two new, often curative, hepatitis C drugs effective March 24, 2015, announced Minister of Health Terry Lake today. People with hepatitis C will be...
by Hepatitis C Research and News on Mar 25, 2015

FDA Safety Alert on Sovaldi/Harvoni Label Change

You are receiving this message as a subscriber to the FDA hepatitis electronic list serve. The purpose of the list serve is to relay important information about viral hepatitis-related products and issues, including product approvals, significant lab...
by Hepatitis C Research and News on Mar 21, 2015

Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment

Published: Nov 11, 2014 8:02 a.m. ET - High Cure Rates in Nearly 800 HCV Patients with Advanced Liver Disease - BOSTON, Nov 11, 2014 (BUSINESS WIRE) -- Gilead Sciences, Inc. GILD, +0.55% today announced results from several Phase 2 and Phase 3 stu...
by Hepatitis C Research and News on Nov 11, 2014

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

10-11-2014 US surveyed specialists anticipate prescribing Gilead Sciences’ (Nasdaq: GILD) Harvoni to a high proportion of their genotype-1 infected hepatitis C virus (HCV) patients, including those with cirrhosis of the liver, even if it is listed...
by Hepatitis C Research and News on Nov 10, 2014

Can a $1000 a Pill Hepatitis C Drug Really Save Prisons Money?

With over 3 million cases of Hepatitis C in the US alone, it comes as no surprise pharmaceutical companies put great resources into testing new medications to help fight the disease. Gilead Sciences of Foster City received approval for a new Hepatiti...
by Debt Free Living Guru on Oct 21, 2014

15 Facts about HARVONI the recent Hepatitis C from Gilead

HARVONI is a combination of ledipasvir (90mg), a (HCV) NS5A inhibitor, and sofosbuvir (400mg), an HCV nucleotide analog NS5B polymerase inhibitor. HARVONI was approved by FDA on... [[ This is a content summary only. Visit my website for full li...
by pharmacy training on Oct 11, 2014

FDA Approves Single-Dose $1125 a Pill Hepatitis C Cure as Breakthrough Drug

A new drug named Harvoni to treat chronic hepatitis C virus genotype 1 infection (HCV) has been approved by the Food and Drug Administration (FDA), but it comes with a hefty $1125 a pill cost. That means a 12 week regimen will cost $94,500, although...
by Debt Free Living Guru on Oct 11, 2014


Trending Topics

Close